Regional Burden of Urinary Tract Infection, Its Aetiologies, and Antibiotic Resistance Patterns, 2020-2023: A Retrospective Study

2020-2023年区域尿路感染负担、病因及抗生素耐药模式:一项回顾性研究

阅读:1

Abstract

BACKGROUND AND AIMS: The emergence of antibiotic-resistant strains of urinary tract infections (UTI) pathogens poses a significant challenge to the effective treatment of this condition. This study aimed to conduct a retrospective study to analyze the etiology and antibiotic resistance patterns of common urinary tract pathogens in the Ashanti Region of Ghana. METHODS: The study employed a standardized data collection form to extract information on age, sex, urine culture results, antibiotic susceptibility test results, and antibiotic treatment regimens from 2020 to 2023. RESULTS: The primary agent responsible for UTIs was Escherichia coli, identified in 47.8% of cases, followed by Klebsiella pneumoniae at 15.8%, Staphylococcus aureus at 9.2%, and Pseudomonas aeruginosa at 6.5%. Candida species were detected in 12% of cases, while coagulase-negative Staphylococci constituted 3.8%. Proteus and Providencia species were observed in 1.1% and 0.5%, respectively. E. coli exhibited complete resistance (100%) to Nalidixic acid (NAL) and Ofloxacin (OFL), with varying degrees of resistance observed across other antibiotics. Among the 29 isolates of K. pneumoniae, 90.0% showed resistance against Cefotaxime, 81.3% against Ciprofloxacin, and 80% against Trimethoprim/Sulfamethoxazole. Sixty percent of E. coli isolates and 25% of Klebsiella isolates demonstrated multi-drug resistance and ESBL production. CONCLUSION: The surge in multidrug-resistant (MDR) gram-negative isolates presents a significant healthcare hurdle for UTI patients. A noteworthy portion of prevalent pathogens, resistant to NAL and OFL, falls into the category of ESBL-producing Enterobacterales and Pseudomonas spp. The limited availability of effective treatments for MDR gram-negative isolates underscores the urgent need for innovative therapeutic alternatives.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。